Skip to main content
editorial
. 2021 Feb 15;10(2):85–93. doi: 10.1159/000514312

Table 3.

Efficacy of lenvatinib on FGFR4 positive HCC (n = 40)

FGFR4-ICH
positive, n = 27
FGFR4-IHC
negative, n = 13
CR, n 0 0
PR, n 22 4
SD, n 3 4
PD, n 2 5
ORR, % 81 31
DCR, % 93 62
PFS, months 5.5 2.5

IHC, immunohistochemical staining; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; HCC, hepatocellular carcinoma. Modified from ref. [22].